Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04156906 · ClinicalTrials.gov registry record · Early Phase 1
RHD Genotype Matched Red Cells for Anti-D
A Early Phase 1 study, sponsored by Children's Hospital of Philadelphia.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 5
- Enrollment target
NCT04156906 is a Early Phase 1 study that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 5 participants.
The verdict
NCT04156906, a Early Phase 1 study, has completed, sponsored by Children's Hospital of Philadelphia.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a pilot study to evaluate the feasibility and safety of providing RH genotype matched D+ Red Blood Cells (RBCs) to chronically transfused patients with sickle cell disease (SCD) who type D+ but have formed anti-D and are currently transfused with D- RBC (Red Blood Cell) units.
Interventions
- BIOLOGICAL D+ RH genotype matched red cell units for transfusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-07-08 |
| Est. Completion | 2024-10-04 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04156906
The ClinicalTrials.gov registry entry for NCT04156906 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which D+ RH genotype matched red cell units for transfusion is the first listed.
NCT04156906 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04156906 about?
NCT04156906 is a clinical study titled "RHD Genotype Matched Red Cells for Anti-D". This is a pilot study to evaluate the feasibility and safety of providing RH genotype matched D+ Red Blood Cells (RBCs) to chronically transfused patients with sickle cell disease (SCD) who type D+ but have formed anti-D and are currently transfused with D- RBC (Red Blood Cell) units.
What is the current status of trial NCT04156906?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2020-07-08. Estimated completion is 2024-10-04.
What interventions are being tested in trial NCT04156906?
The interventions under investigation include: D+ RH genotype matched red cell units for transfusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT04156906?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.